At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed B-cell non-Hodgkin's lymphoma
- ✓DLBCL (NOS or associated subtypes per WHO 2016)
- ✓High-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
- ✓Primary mediastinal (thymic) large B cell lymphoma
- ✕Primary CNS lymphoma (not applicable to CNS cohort)
- ✕Richter's transformed DLBCL from CLL (not applicable to RT cohort)
- ✕Unable to give informed consent
- ✕Known history of HIV or active hepatitis B (HBsAg positive)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, and 2 other interventions for Refractory Diffuse Large B Cell Lymphoma (DLBCL) and 7 related conditions. Currently recruiting, targeting 248 participants across 25 sites in 2 countries.
Signals
Detailed Summary
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy. Additional cohorts include subjects with B-cell primary or secondary central nervous system (CNS) lymphoma (PCNSL) and (SCNSL), mantle cell lymphoma (MCL) and Richter's transformation (RT) after receiving at least one line of therapy.
Study Details
Timeline
Interventions
Chimeric antigen receptor (CAR) T cell therapy
Lymphodepleting chemotherapy
Lymphodepleting chemotherapy
Lymphodepleting chemotherapy